Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation
Alyanna M Popatia, Ahmad Sharanek, Arezu Jahani-Asl · 2026
Read Glycobiology-driven therapeutic targeting of glycan-binding proteins: mechanisms, diseases, and clinical translation by Alyanna M Popatia, Ahmad Sharanek, Arezu Jahani-Asl (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13241506.txt.
Description
Galectins, a family of proteins that bind sugar chains on other molecules, take center stage in a review by Popatia and colleagues at the University of Ottawa. The authors map how these proteins steer signaling inside and outside cells. Sixteen mammalian galectins fall into three structural types, each with its own binding habits. Their influence reaches growth, blood vessel formation, and immune control.
Across diseases, the review links galectins to cancer spread, heart and vessel damage, brain degeneration, metabolic problems, and autoimmunity. Some family members push in opposite directions depending on tissue, which complicates drug design. Trials already test blockers ranging from modified carbohydrates and pectins to antibodies. New tools such as single-cell glyco-RNA sequencing and CRISPR glycoengineering may sharpen future galectin drugs.
Catalog record
| CREATOR | Alyanna M Popatia, Ahmad Sharanek, Arezu Jahani-Asl |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 111 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |